Sudhir Unni
YOU?
Author Swipe
View article: Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States Open
This study demonstrated the heterogeneity of treatments after 1L PBC-containing therapy for patients with ES-SCLC, with no clear standard of care identified. In 3L, rwTTD/D, rwTTNT/D, and rwOS were short, demonstrating the substantial unme…
View article: Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial
Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial Open
Introduction: The global, randomized, placebo (Pbo)-controlled, phase 3 QuANTUM-First trial (NCT02668653) evaluated quizartinib (Quiz), a novel oral FLT3 inhibitor, in combination with induction and consolidation chemotherapy, and as maint…
View article: Evaluating the Usefulness of HEAR Score in Stratifying Patients with Suspected Non-ST Elevation Myocardial Infarction: A Retrospective Observational Study
Evaluating the Usefulness of HEAR Score in Stratifying Patients with Suspected Non-ST Elevation Myocardial Infarction: A Retrospective Observational Study Open
View article: PB2303: REAL-WORLD TREATMENT PATTERNS AND ADVERSE EVENTS AMONG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE DATABASE STUDY
PB2303: REAL-WORLD TREATMENT PATTERNS AND ADVERSE EVENTS AMONG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE DATABASE STUDY Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Peripheral T-cell lymphomas (PTCL) are a rare and aggressive form of non-Hodgkin’s lymphoma that develop from mature T-cells and natural killer cells. Due to the diversity o…
View article: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study Open
TMB levels greater than or equal to 10 mut/Mb, when tested by Foundation Medicine or Caris at treatment initiation, were significantly associated with improved OS and PFS among patients treated with first-line immunotherapy-containing regi…
View article: Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study Open
View article: Health care resource utilization and costs of recurrent <i>Clostridioides difficile</i> infection in the elderly: a real-world claims analysis
Health care resource utilization and costs of recurrent <i>Clostridioides difficile</i> infection in the elderly: a real-world claims analysis Open
BACKGROUND: Clostridioides difficile infection (CDI) affected an estimated 365,000 persons in the United States in 2017. Despite a nationally decreasing trend of CDI cases, the population incidence of recurrent CDI (rCDI) has…
View article: Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer Open
Background Breast cancer costs were estimated at $16.5 billion in 2010 and were higher than other cancer costs. There are limited studies on breast cancer charges and costs by BRCA mutations and receptor status. We examined overall health …
View article: Estimation of Healthcare-related Charges in Women with BRCA Mutations and Breast Cancer&nbsp;
Estimation of Healthcare-related Charges in Women with BRCA Mutations and Breast Cancer Open
BackgroundBreast cancer costs were estimated at $16.5 billion in 2010 and were higher than other cancer costs. There are limited studies on breast cancer charges and costs by BRCA mutations and receptor status. We examined overall health c…
View article: Estimation of Healthcare-related Charges in Women with BRCA Mutations and Breast Cancer
Estimation of Healthcare-related Charges in Women with BRCA Mutations and Breast Cancer Open
Background Breast cancer costs were estimated at $16.5 billion in 2010, and were higher than other cancer costs. There are limited studies on breast cancer charges and costs by BRCA mutations and receptor status. We examined overall health…
View article: Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes
Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes Open
Aims To identify change in glycated haemoglobin (HbA1c) for 1 year after treatment intensification in patients with HbA1c >53 mmol/mol (7.0%) while on two classes of oral antidiabetic drugs (OADs). Material and methods A retrospective coho…
View article: Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents
Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents Open
Research funding was provided by Sanofi to the Pharmacotherapy Outcomes Research Center at the University of Utah and SelectHealth to conduct this study. Thomas, Sterling, and Johnstone are employees and stock/shareholders of Sanofi. Kim, …
View article: Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes
Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes Open
The study was funded by a collaborative research grant from AstraZeneca. Employees of AstraZeneca participated in most aspects of the study and in manuscript preparation. Nguyen and Hurd are employed by, and hold stock in, AstraZeneca. McA…
View article: Table of Contents
Table of Contents Open
View article: Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis
Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis Open
Exenatide QW and liraglutide lead to similar HbA1c and weight reductions at 1 year in the real-world setting. Greater HbA1c reductions occurred in insulin-naive patients with baseline HbA1c ≥7.0%. Both agen…
View article: BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study Open
View article: Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States
Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Open
There is room for better LDL-C management among high-risk CVD patients to reduce their overall CV risk.